Vanmiddag vindt de officiële opening plaats van de nieuwe behuizing van Prosensa in Leiden. Het succesvolle biofarmaceutische bedrijf verhuist met het oog op de exponentiële groei die het sinds 2009 doormaakt. Prosensa ontwikkelt onder meer een therapie tegen de ernstige spierziekte van Duchenne, die bij 1 op de 3500 geboren jongens voorkomt.
Blog posts
Pronota and Molecuence announce collaboration in protein biomarker discovery.
Ghent, Belgium, 22th February 2011 – Pronota NV today announced that it has entered into an agreement with Molecuence Corporation, a wholly owned subsidiary of Mitsubishi Chemical Corporation, to discover and validate protein biomarkers in stroke. Pronota will apply its proven proprietary platforms for protein biomarker discovery (MASStermind®) and biomarker verification MASSterclass™) to this project.… Continue reading Pronota and Molecuence announce collaboration in protein biomarker discovery.
GSK and Prosensa announce start of Phase III study of investigational Duchenne Muscular Dystrophy medication
Leiden, January 19, 2011 – GlaxoSmithKline (GSK) and Prosensa today announced that the first patient has commenced treatment in the Phase III clinical study investigating GSK2402968, in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip (up to 13% of boys with DMD). Commencement of… Continue reading GSK and Prosensa announce start of Phase III study of investigational Duchenne Muscular Dystrophy medication
Kiadis Pharma signs license agreement with Hospira to commercialize ATIR™ in Europe and Asia – Partnership would advance innovative stem cell transplant product
Kiadis Pharma, a biopharmaceutical company based in The Netherlands, announced that it has entered into a licensing agreement with Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical company, to develop and commercialize Kiadis Pharma’s ATIR™. ATIR™ is a personalized hematology product designed for blood cancer patients in need of allogeneic bone marrow transplantation who cannot… Continue reading Kiadis Pharma signs license agreement with Hospira to commercialize ATIR™ in Europe and Asia – Partnership would advance innovative stem cell transplant product
Dr. Petr Neuzil to Present His Experience with the iVAC3L at EUMS 2010
Dr. Petr Neuzil from Na Homolce Hospital, Prague, the Czech Republic will be making a presentation on his experience with the iVAC 3L in a cath-lab at the EUMS, 2010 on December 4th during the session entitled “Emerging New Technologies”, between 11:45am – 14:00pm.
